MDMB-CHMINACA[1] (also known as MDMB(N)-CHM) is an
indazole-based
synthetic cannabinoid that acts as a potent
agonist of the
CB1 receptor,[2] and has been sold online as a
designer drug.[3][4][5][6][7] It was invented by
Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a
binding affinity of 0.0944 nM at
CB1, and an EC50 of 0.330 nM.[8] It is closely related to
MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication.[9]
Legal status
MDMB-CHMINACA is a Fifth Schedule of the Misuse of Drugs Act (MDA) controlled substance in Singapore as of May 2015.[10]
MDMB-CHMINACA is illegal in Germany, Switzerland as of December 2015.[11]
Sweden's public health agency suggested classifying MDMB-CHMINACA as a hazardous substance, on September 25, 2019.[12]
^Pulver, Benedikt; Fischmann, Svenja; Gallegos, Ana; Christie, Rachel (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276.
doi:
10.1002/dta.3403.
^Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–54.
doi:
10.1021/acschemneuro.6b00137.
PMID27421060.
^Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (August 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry. 407 (21): 6301–15.
doi:
10.1007/s00216-015-8612-7.
PMID25893797.
S2CID31838655.
^Hess C, Murach J, Krueger L, Scharrenbroch L, Unger M, Madea B, Sydow K (May 2017). "Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples". Drug Testing and Analysis. 9 (5): 721–733.
doi:
10.1002/dta.2030.
PMID27400642.
^"Очередная жертва спайса" (in Russian). Federal Drug Control Service of the Russian Federation. 17 March 2015. Archived from
the original on 14 July 2015. Retrieved 13 July 2015.
^"CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Archived from
the original on 15 July 2015. Retrieved 14 July 2015.
MDMB-CHMINACA[1] (also known as MDMB(N)-CHM) is an
indazole-based
synthetic cannabinoid that acts as a potent
agonist of the
CB1 receptor,[2] and has been sold online as a
designer drug.[3][4][5][6][7] It was invented by
Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a
binding affinity of 0.0944 nM at
CB1, and an EC50 of 0.330 nM.[8] It is closely related to
MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication.[9]
Legal status
MDMB-CHMINACA is a Fifth Schedule of the Misuse of Drugs Act (MDA) controlled substance in Singapore as of May 2015.[10]
MDMB-CHMINACA is illegal in Germany, Switzerland as of December 2015.[11]
Sweden's public health agency suggested classifying MDMB-CHMINACA as a hazardous substance, on September 25, 2019.[12]
^Pulver, Benedikt; Fischmann, Svenja; Gallegos, Ana; Christie, Rachel (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276.
doi:
10.1002/dta.3403.
^Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–54.
doi:
10.1021/acschemneuro.6b00137.
PMID27421060.
^Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (August 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry. 407 (21): 6301–15.
doi:
10.1007/s00216-015-8612-7.
PMID25893797.
S2CID31838655.
^Hess C, Murach J, Krueger L, Scharrenbroch L, Unger M, Madea B, Sydow K (May 2017). "Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples". Drug Testing and Analysis. 9 (5): 721–733.
doi:
10.1002/dta.2030.
PMID27400642.
^"Очередная жертва спайса" (in Russian). Federal Drug Control Service of the Russian Federation. 17 March 2015. Archived from
the original on 14 July 2015. Retrieved 13 July 2015.
^"CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Archived from
the original on 15 July 2015. Retrieved 14 July 2015.